Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Next Previous
Search
Trial Profile

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary) ; Sintilimab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 28 Jul 2021 According to a Hutchmed media release, data from this study were presented at the 2021 ASCO Annual Meeting.
    • 04 Mar 2021 According to a Hutchison China MediTech Limited media release, the company expect to present preliminary data in CRC in mid-2021.
    • 31 May 2020 Results (n=52) assessing efficiency of combination of Fruquintinib with Sintilimab in metastatic colorectal cancer patients, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top